AHU-377 hemicalcium saltPotent neprilysin inhibitor CAS# 1369773-39-6 |
- Amyloid β-Protein (1-15)
Catalog No.:BCC1003
CAS No.:183745-81-5
- Beta-Amyloid (1-11)
Catalog No.:BCC1002
CAS No.:190436-05-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1369773-39-6 | SDF | Download SDF |
| PubChem ID | 91827885 | Appearance | Powder |
| Formula | C48H56CaN2O10 | M.Wt | 861.0 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | AHU 377 | ||
| Solubility | DMSO : 125 mg/mL (290.35 mM; Need ultrasonic) | ||
| Chemical Name | calcium;4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate | ||
| SMILES | CCOC(=O)C(C)CC(CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].CCOC(=O)C(C)CC(CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].[Ca+2] | ||
| Standard InChIKey | DDLCKLBRBPYKQS-OXXXZDCLSA-L | ||
| Standard InChI | InChI=1S/2C24H29NO5.Ca/c2*1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19;/h2*4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28);/q;;+2/p-2/t2*17-,21+;/m11./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Membrane metallo-endopeptidase (neprilysin) inhibitor prodrug. Increases ANF-induced natriuresis without affecting diuresis in rats. Orally bioavailable. |
AHU-377 hemicalcium salt Dilution Calculator
AHU-377 hemicalcium salt Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.1614 mL | 5.8072 mL | 11.6144 mL | 23.2288 mL | 29.036 mL |
| 5 mM | 0.2323 mL | 1.1614 mL | 2.3229 mL | 4.6458 mL | 5.8072 mL |
| 10 mM | 0.1161 mL | 0.5807 mL | 1.1614 mL | 2.3229 mL | 2.9036 mL |
| 50 mM | 0.0232 mL | 0.1161 mL | 0.2323 mL | 0.4646 mL | 0.5807 mL |
| 100 mM | 0.0116 mL | 0.0581 mL | 0.1161 mL | 0.2323 mL | 0.2904 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
AHU-377 hemicalcium salt is a hemicalcium salt form of AHU-377. It is an inhibitor of neprilysin with IC50 value of 5 nM [1].
AHU-377 and the angiotensin II AT1 receptor antagonist valsartan compose LCZ696 in a 1:1 molar ratio. LCZ696 is an angiotensin receptor neprilysin inhibitor. It can reduce blood pressure and may be a novel drug for the treatment of heart failure. AHU-377 is a pro-drug, it can be converted by enzymatic cleavage of the ethyl ester into the active form LBQ657. It is reported that AHU-377(30 and 100 mg/kg, PO) can cause antihypertensive effect in a dose-dependent manner in DAHI-SS rats. But in the DOCA-salt hypertensive rats, it shows a weak reduction [2, 3].
References: [1] Ksander GM, Ghai RD, deJesus R, Diefenbacher CG, Yuan A, Berry C, Sakane Y, Trapani A. Dicarboxylic acid dipeptide neutral endopeptidase inhibitors. J Med Chem. 1995 May 12; 38(10):1689-700. [2] Voors AA, Dorhout B, van der Meer P. The potential role of valsartan + AHU377 ( LCZ696 ) in the treatment of heart failure. Expert Opin Investig Drugs. 2013 Aug;22(8):1041-7. [3] Laxminarayan G Hegde, Cecile Yu, Cheruvu Madhavi et al. Comparative efficacy of AHU-377, a potent neprilysin inhibitor, in two rat models of volume-dependent hypertension. BMC Pharmacology 2011, 11(Suppl 1):P33.
- Macranthoidin B
Catalog No.:BCN5938
CAS No.:136849-88-2
- TOTU
Catalog No.:BCC2826
CAS No.:136849-72-4
- 1-Dehydro-10-gingerdione
Catalog No.:BCN3338
CAS No.:136826-50-1
- Delavirdine
Catalog No.:BCC4300
CAS No.:136817-59-9
- 6-O-Cinnamoylcatalpol
Catalog No.:BCN6193
CAS No.:136807-41-5
- [Ser25] Protein Kinase C (19-31)
Catalog No.:BCC1022
CAS No.:136795-05-6
- Lubiprostone
Catalog No.:BCC4918
CAS No.:136790-76-6
- Goniodiol diacetate
Catalog No.:BCN3956
CAS No.:136778-40-0
- Retinyl glucoside
Catalog No.:BCC1891
CAS No.:136778-12-6
- Gallic aldehyde
Catalog No.:BCN7859
CAS No.:13677-79-7
- 4,4'-Bismaleimidodiphenylmethane
Catalog No.:BCC8662
CAS No.:13676-54-5
- Minimolide F
Catalog No.:BCN6424
CAS No.:1367351-41-4
- (-)-Syringaresnol-4-O-beta-D-apiofuranosyl-(1->2)-beta-D-glucopyranoside
Catalog No.:BCN1578
CAS No.:136997-64-3
- Sophoraflavanone H
Catalog No.:BCN6864
CAS No.:136997-68-7
- Sophoraflavanone I
Catalog No.:BCN6863
CAS No.:136997-69-8
- Calcium pantothenate
Catalog No.:BCN8503
CAS No.:137-08-6
- Lidocaine
Catalog No.:BCC1084
CAS No.:137-58-6
- L-Ascorbyl 6-palmitate
Catalog No.:BCC4915
CAS No.:137-66-6
- Amprolium HCl
Catalog No.:BCC4626
CAS No.:137-88-2
- 3',4'-Di-O-acetyl-2',6'-di-O-p-coumaroylastragalin
Catalog No.:BCN6610
CAS No.:137018-33-8
- PRT062607 Hydrochloride
Catalog No.:BCC1869
CAS No.:1370261-97-4
- Pseudoginsenoside Rh2
Catalog No.:BCC8353
CAS No.:1370264-16-6
- Episyringaresinol 4'-O-β-D-glncopyranoside
Catalog No.:BCC8957
CAS No.:137038-13-2
- Walsuralactam A
Catalog No.:BCN6734
CAS No.:1370556-82-3
Dicarboxylic acid dipeptide neutral endopeptidase inhibitors.[Pubmed:7752193]
J Med Chem. 1995 May 12;38(10):1689-700.
The synthesis of three series of dicarboxylic acid dipeptide neutral endopeptidase 24.11 (NEP) inhibitors is described. In particular, the amino butyramide 21a exhibited potent NEP inhibitory activity (IC50 = 5.0 nM) in vitro and in vivo. Blood levels of 21a were determined using an ex vivo method by measuring plasma inhibitory activity in conscious rats, mongrel dogs, and cynomolgus monkeys. Free drug concentrations were 10-1500 times greater than the inhibitory constant for NEP over the course of a 6 h experiment. A good correlation of free drug concentrations was obtained when comparing values determined by the ex vivo analysis to those calculated from direct HPLC measurements. Plasma atrial natriuretic factor (exogenous) levels were elevated in rats and dogs after oral administration of 19a. Urinary volume and urinary sodium excretion were also potentiated in anesthetized dogs treated with 21a.
